All Stories

  1. Correction: Preclinical evaluation of glycan-targeting monoclonal antibodies for bimodal near-infrared fluorescence and photoacoustic imaging of gastrointestinal cancers

    Article • EJNMMI Research, September 2025, Springer Science + Business Media

    Dr. CFM Sier

  2. Preclinical evaluation of glycan-targeting monoclonal antibodies for bimodal near-infrared fluorescence and photoacoustic imaging of gastrointestinal cancers

    Article • EJNMMI Research, June 2025, Springer Science + Business Media

    Dr. CFM Sier

  3. Fluorescent Nanobodies for enhanced guidance in digestive tumors and liver metastasis surgery

    Article • European Journal of Surgical Oncology, March 2025, Elsevier

    Dr. CFM Sier

  4. Modulation of the Tumor Stroma and Associated Novel Nanoparticle Strategies to Enhance Tumor Targeting

    Article • Surgeries, February 2024, MDPI AG

    Dr. CFM Sier

  5. Introduction to a Novel End-of-the-Year Special Issue of Surgeries

    Article • Surgeries, December 2023, MDPI AG

    Dr. CFM Sier

  6. Evaluation of Potential Targets for Fluorescence-Guided Surgery in Pediatric Ewing Sarcoma: A Preclinical Proof-of-Concept Study

    Article • Cancers, July 2023, MDPI AG

    Dr. CFM Sier

  7. Data from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  8. Data from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  9. Supplementary figures S1-S5 from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  10. Supplementary figures S1-S5 from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  11. Supplementary table 1 and 2 from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  12. Supplementary table 1 and 2 from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  13. Immunohistochemical Evaluation of Candidate Biomarkers for Fluorescence-Guided Surgery of Myxofibrosarcoma Using an Objective Scoring Method

    Article • Biomedicines, March 2023, MDPI AG

    Dr. CFM Sier

  14. Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas

    Article • Cancers, March 2023, MDPI AG

    Dr. CFM Sier

  15. Intraoperative Imaging Techniques to Improve Surgical Resection Margins of Oropharyngeal Squamous Cell Cancer: A Comprehensive Review of Current Literature

    Article • Cancers, January 2023, MDPI AG

    Professor Orlando Guntinas-Lichius, Dr. CFM Sier

  16. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy

    Article • Cancers, December 2021, MDPI AG

    Dr. CFM Sier

  17. Integrin αvβ6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions

    Article • Cancers, November 2021, MDPI AG

    Dr. CFM Sier

  18. An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma

    Article • Cancers, November 2021, MDPI AG

    Dr. CFM Sier

  19. Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review

    Article • Biomedicines, October 2021, MDPI AG

    Dr. CFM Sier

  20. NIR Fluorescence Imaging of Colon Cancer With cRGD-ZW800-1—Response

    Article • Clinical Cancer Research, September 2021, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  21. Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review

    Article • International Journal of Molecular Sciences, April 2021, MDPI AG

    Professor Paul HA Quax, Dr. CFM Sier

  22. CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy

    Article • Diagnostics, March 2021, MDPI AG

    Dr. CFM Sier

  23. A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma

    Article • European Journal of Cancer, March 2021, Elsevier

    Dr. CFM Sier

  24. Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review

    Article • Cancers, February 2021, MDPI AG

    Dr. CFM Sier

  25. Cell-Based Tracers as Trojan Horses for Image-Guided Surgery

    Article • International Journal of Molecular Sciences, January 2021, MDPI AG

    Dr. CFM Sier

  26. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging

    Article • Cancers, December 2020, MDPI AG

    Dr. CFM Sier

  27. Vitamin D in Head and Neck Cancer: a Systematic Review

    Article • Current Oncology Reports, November 2020, Springer Science + Business Media

    Dr. CFM Sier

  28. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma

    Article • Scientific Reports, October 2020, Springer Science + Business Media

    Dr. CFM Sier

  29. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment

    Article • Scientific Reports, October 2020, Springer Science + Business Media

    Dr. CFM Sier

  30. Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study

    Article • Molecular Imaging and Biology, August 2020, Springer Science + Business Media

    Dr. CFM Sier

  31. Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer

    Article • Pharmaceuticals, July 2020, MDPI AG

    Dr. CFM Sier

  32. Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer

    Article • EJNMMI Research, July 2020, Springer Science + Business Media

    Dr. CFM Sier, Professor Paul HA Quax

  33. Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases

    Article • Cancers, June 2020, MDPI AG

    Dr. CFM Sier

  34. EGFR and αvβ6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region

    Article • Cancers, June 2020, MDPI AG

    Dr. CFM Sier

  35. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

    Article • Clinical Cancer Research, April 2020, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  36. Welcome to Surgeries: A New Open Access Platform for Clinical and Experimental Research and Developments in All Fields of Surgery

    Article • Surgeries, March 2020, MDPI AG

    Dr. CFM Sier

  37. Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: A systematic review of candidate biomarkers

    Article • Gynecologic Oncology, March 2020, Elsevier

    Dr. CFM Sier

  38. Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging

    Article • Molecular Diagnosis & Therapy, February 2020, Springer Science + Business Media

    Dr. CFM Sier

  39. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer

    Article • Science Advances, September 2019, American Association for the Advancement of Science

    Dr. CFM Sier

  40. A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer

    Article • European Journal of Histochemistry, May 2019, PAGEPress Publications

    Dr. CFM Sier

  41. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer

    Article • BMC Cancer, March 2019, Springer Science + Business Media

    Dr. CFM Sier

  42. Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation

    Article • Surgical Oncology, March 2019, Elsevier

    Dr. CFM Sier

  43. Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma

    Article • Journal of Surgical Oncology, September 2018, Wiley

    Dr. CFM Sier, Professor Pancras C.W. Hogendoorn

  44. Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis

    Article • Clinical Cancer Research, June 2018, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  45. Targeting integrin alpha5 receptor in pancreatic stellate cells to diminish tumor-promoting effects in pancreatic cancer

    Article • June 2018, Cold Spring Harbor Laboratory Press

    Dr. CFM Sier

  46. Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy

    Article • OncoTargets and Therapy, March 2018, Dove Medical Press

    Dr. CFM Sier

  47. Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma

    Article • International Journal of Cancer, January 2018, Wiley

    Dr. CFM Sier

  48. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma

    Article • Oncotarget, May 2017, Impact Journals, LLC

    Dr. CFM Sier

  49. Morphological and phenotypical features of ovarian metastases in breast cancer patients

    Article • BMC Cancer, March 2017, Springer Science + Business Media

    Dr. CFM Sier

  50. uPAR directed-imaging of head-and-neck cancer

    Article • Oncotarget, March 2017, Impact Journals, LLC

    Dr. CFM Sier

  51. Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer

    Article • Oral Oncology, March 2017, Elsevier

    Dr. CFM Sier

  52. Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types

    Article • Oncotarget, February 2017, Impact Journals, LLC

    Dr. CFM Sier

  53. Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery

    Article • International Journal of Molecular Sciences, February 2017, MDPI AG

    Dr. CFM Sier

  54. Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue

    Article • Biomarkers in Cancer, January 2017, SAGE Publications

    Dr. CFM Sier

  55. In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer

    Article • Biomarkers in Cancer, January 2017, SAGE Publications

    Dr. CFM Sier

  56. Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells

    Article • Biomarker Insights, January 2017, SAGE Publications

    Dr. CFM Sier

  57. Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery

    Article • November 2016, MDPI AG

    Dr. CFM Sier

  58. EpCAM as multi-tumour target for near-infrared fluorescence guided surgery

    Article • BMC Cancer, November 2016, Springer Science + Business Media

    Dr. CFM Sier

  59. Selecting tumor targets for dummies

    Article • Biomarkers in Cancer, September 2016, SAGE Publications

    Dr. CFM Sier

  60. Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery

    Article • Molecular Imaging and Biology, April 2016, Springer Science + Business Media

    Dr. CFM Sier

  61. Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue

    Article • Archives of Gynecology and Obstetrics, March 2016, Springer Science + Business Media

    Dr. CFM Sier

  62. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer

    Article • Oncogene, January 2016, Springer Science + Business Media

    Dr. CFM Sier

  63. Stromal Targets for Fluorescent-Guided Oncologic Surgery

    Article • Frontiers in Oncology, November 2015, Frontiers

    Dr. CFM Sier

  64. Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors

    Article • International Journal of Cancer, June 2015, Wiley

    Dr. CFM Sier

  65. uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery

    Article • Oncotarget, March 2015, Impact Journals, LLC

    Dr. CFM Sier

  66. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer

    Article • British Journal of Cancer, May 2014, Nature

    Dr. CFM Sier

  67. Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study

    Article • BMC Cancer, April 2014, Springer Science + Business Media

    Dr. CFM Sier

  68. Bone healing and Mannose-Binding Lectin

    Article • International Journal of Surgery, May 2013, Elsevier

    Dr. CFM Sier

  69. Cytoplasmic Overexpression of HER2: A Key Factor in Colorectal Cancer

    Article • Clinical Medicine Insights Oncology, January 2013, SAGE Publications

    Dr. CFM Sier

  70. Circulating bone morphogenetic protein levels and delayed fracture healing

    Article • International Orthopaedics, December 2012, Springer Science + Business Media

    Dr. CFM Sier

  71. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts

    Article • Oncogene, December 2012, Springer Science + Business Media

    Dr. CFM Sier

  72. Injury pattern, injury severity, and mortality in 33,495 hospital-admitted victims of motorized two-wheeled vehicle crashes in The Netherlands

    Article • Journal of Trauma and Acute Care Surgery, May 2012, Wolters Kluwer Health

    Dr. CFM Sier

  73. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients

    Article • British Journal of Cancer, April 2012, Springer Science + Business Media

    Dr. CFM Sier

  74. Reply to the letter to the editor: Could the use of bone morphogenetic proteins in fracture healing do more harm than good to our patients?

    Article • International Orthopaedics, December 2011, Springer Science + Business Media

    Dr. CFM Sier

  75. Displaced midshaft fractures of the clavicle: non-operative treatment versus plate fixation (Sleutel-TRIAL). A multicentre randomised controlled trial

    Article • BMC Musculoskeletal Disorders, August 2011, Springer Science + Business Media

    Dr. CFM Sier

  76. Use and efficacy of bone morphogenetic proteins in fracture healing

    Article • International Orthopaedics, June 2011, Springer Science + Business Media

    Dr. CFM Sier

  77. Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients

    Article • Current Pharmaceutical Design, June 2011, Bentham Science Publishers

    Professor Paul HA Quax, Dr. CFM Sier

  78. Implant removal associated complications in children with limb fractures due to trauma

    Article • European Journal of Trauma and Emergency Surgery, March 2011, Springer Science + Business Media

    Dr. CFM Sier

  79. Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer

    Article • World Journal of Gastrointestinal Oncology, January 2011, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr. CFM Sier

  80. Matrix Metalloproteinase-14 (MT1-MMP)-Mediated Endoglin Shedding Inhibits Tumor Angiogenesis

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Dr. CFM Sier

  81. 5-Aminosalicylic acid inhibits TGF-β1 signalling in colorectal cancer cells

    Article • Cancer Letters, January 2010, Elsevier

    Dr. CFM Sier

  82. Clinical significance of stromal apoptosis in colorectal cancer

    Article • British Journal of Cancer, August 2009, Springer Science + Business Media

    Dr. CFM Sier

  83. Expression of endoglin (CD105) in cervical cancer

    Article • British Journal of Cancer, April 2009, Springer Science + Business Media

    Dr. CFM Sier

  84. Active TGF-β1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence

    Article • Cancer Science, April 2009, Wiley

    Dr. CFM Sier

  85. Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohnʼs disease

    Article • Inflammatory Bowel Diseases, January 2009, Oxford University Press (OUP)

    Dr. CFM Sier

  86. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis

    Article • European Journal of Cancer, September 2008, Elsevier

    Dr. CFM Sier

  87. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not

    Article • British Journal of Cancer, May 2008, Springer Science + Business Media

    Dr. CFM Sier

  88. Efficient degradation-aided selection of protease inhibitors by phage display

    Article • Biochemical and Biophysical Research Communications, December 2007, Elsevier

    Dr. CFM Sier

  89. Endothelium specific matrilysin (MMP-7) expression in human cancers

    Article • Matrix Biology, October 2007, Elsevier

    Dr. CFM Sier

  90. Eradication of Helicobacter pylori Infection Favourably Affects Altered Gastric Mucosal MMP-9 Levels

    Article • Helicobacter, October 2007, Wiley

    Dr. CFM Sier

  91. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer

    Article • European Journal of Cancer, August 2007, Elsevier

    Dr. CFM Sier

  92. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype

    Article • Digestive and Liver Disease, August 2007, Elsevier

    Dr. CFM Sier

  93. Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients

    Article • British Journal of Cancer, July 2007, Springer Science + Business Media

    Dr. CFM Sier

  94. Determination of matrilysin activity in gastrointestinal neoplasia

    Article • European Journal of Clinical Investigation, July 2007, Wiley

    Dr. CFM Sier

  95. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer

    Article • British Journal of Cancer, August 2006, Springer Science + Business Media

    Dr. CFM Sier

  96. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces β-glucan-dependent CR3-dependent cellular cytotoxicity

    Article • European Journal of Immunology, April 2006, Wiley

    Dr. CFM Sier

  97. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer

    Article • British Journal of Cancer, March 2006, Springer Science + Business Media

    Dr. CFM Sier

  98. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma

    Article • International Journal of Cancer, January 2006, Wiley

    Dr. CFM Sier

  99. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases

    Article • Digestive and Liver Disease, August 2005, Elsevier

    Dr. CFM Sier

  100. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation

    Article • International Journal of Cancer, January 2004, Wiley

    Dr. CFM Sier

  101. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice

    Article • Thrombosis and Haemostasis, January 2004, Thieme Publishing Group

    Dr. CFM Sier

  102. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma

    Article • Cancer, October 2003, Wiley

    Dr. CFM Sier

  103. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage

    Article • Brain, October 2001, Oxford University Press (OUP)

    Dr. CFM Sier

  104. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor

    Article • FEBS Letters, August 2001, Wiley

    Dr. CFM Sier

  105. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices

    Article • Blood, May 2001, American Society of Hematology

    Dr. CFM Sier

  106. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo

    Article • FEBS Letters, June 2000, Wiley

    Dr. CFM Sier

  107. MMP-9 Activity in Urine from Patients with Various Tumors, as Measured by a Novel MMP Activity Assay Using Modified Urokinase as a Substrate

    Article • Annals of the New York Academy of Sciences, June 1999, Wiley

    Dr. CFM Sier

  108. Superoxide dismutases in relation to the overall survival of colorectal cancer patients

    Article • British Journal of Cancer, October 1998, Springer Science + Business Media

    Dr. CFM Sier

  109. High performance density gradient electrophoresis of subcellular organelles, protein complexes and proteins

    Article • Electrophoresis, June 1998, Wiley

    Dr. CFM Sier

  110. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer

    Article • British Journal of Cancer, June 1997, Springer Science + Business Media

    Dr. CFM Sier

  111. Gastric mucosal plasminogen activators inHelicobacter pylori infection

    Article • Digestive Diseases and Sciences, August 1996, Springer Science + Business Media

    Dr. CFM Sier

  112. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma

    Article • British Journal of Cancer, August 1996, Springer Science + Business Media

    Dr. CFM Sier

  113. The effect of treatment of Helicobacter pylori infection on gastric mucosal plasminogen activators

    Article • Fibrinolysis and Proteolysis, June 1996, Elsevier

    Dr. CFM Sier

  114. Prognostic value of the plasminogen activation system in patients with gastric carcinoma

    Article • Cancer, March 1996, Wiley

    Dr. CFM Sier

  115. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer

    Article • European Journal of Cancer, July 1995, Elsevier

    Dr. CFM Sier

  116. Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis

    Article • British Journal of Cancer, February 1995, Springer Science + Business Media

    Dr. CFM Sier

  117. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis

    Article • Gastroenterology, November 1994, Elsevier

    Professor Paul HA Quax, Dr. CFM Sier

  118. Tetranectin expression in human colonic neoplasia

    Article • Histopathology, November 1994, Wiley

    Dr. CFM Sier

  119. Urokinase receptor and colorectal cancer survival

    Article • The Lancet, August 1994, Elsevier

    Dr. CFM Sier

  120. Glutathione S-transferases in liver metastases of colorectal cancer. A comparison with normal liver and primary carcinomas

    Article • Carcinogenesis, January 1994, Oxford University Press (OUP)

    Dr. CFM Sier

  121. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

    Article • Gut, January 1993, BMJ

    Dr. CFM Sier

  122. Association of aneuploidy in index adenomas with metachronous colorectal adenoma development and a comparison

    Article • Cancer, October 1992, Wiley

    Dr. CFM Sier

  123. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia

    Article • Gastroenterology, December 1991, Elsevier

    Dr. CFM Sier

  124. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum

    Article • Histopathology, September 1991, Wiley

    Dr. CFM Sier

  125. Matrix Metalloproteinases in Chronic Liver Disease and Liver Transplantation

    Article • Springer Science + Business Media

    Dr. CFM Sier